---
layout: full_article
title: "Predictive Factors Influencing the Outcomes of Double “J” Stent Placement in Stage IIIB Cervical Cancer Patients With Hydronephrosis Complication"
author: "Gusti Ngurah Krisna Dinatha, Anak Agung Gede Oka, Kadek Budi Santosa"
categories: jbn
canonical_url: https://jurnal.harianregional.com/jbn/full-80501 
citation_abstract_html_url: "https://jurnal.harianregional.com/jbn/id-80501"
citation_pdf_url: "https://jurnal.harianregional.com/jbn/full-80501"  
comments: true
---

<img src="https://jurnal.harianregional.com/media/80501-1.jpg" alt="" style="width:70pt;height:27pt;">
<p><span class="font0" style="font-weight:bold;">DIRECTORY OF</span></p>
<p><span class="font0" style="font-weight:bold;">OPEN ACCESS</span></p>
<p><span class="font0" style="font-weight:bold;">JOURNALS</span></p>
<p><span class="font4">P-ISSN:</span><a href="http://u.lipi.go.id/1481204884"><span class="font4"> 2548-5962</span></a></p>
<p><span class="font4">E-ISSN:</span><a href="http://u.lipi.go.id/1483969293"><span class="font4"> 2548-981X</span></a></p>
<div><a name="caption1"></a>
<h1><a name="bookmark0"></a><span class="font3" style="font-weight:bold;"><a name="bookmark1"></a>ΘB^I≡L ARTICLE</span></h1>
</div><br clear="all">
<div>
<p><a href="https://ojs.unud.ac.id/index.php/jbn"><span class="font4">https://ojs.unud.ac.id/index.php/jbn</span></a></p>
</div><br clear="all">
<div><img src="https://jurnal.harianregional.com/media/80501-2.jpg" alt="" style="width:103pt;height:65pt;">
</div><br clear="all">
<p><span class="font8" style="font-weight:bold;">Predictive Factors Influencing the Outcomes of Double “J” Stent Placement in Stage IIIB Cervical Cancer Patients With Hydronephrosis Complication</span></p>
<p><span class="font6" style="font-weight:bold;">Gusti Ngurah Krisna Dinatha<sup>1*</sup>, Anak Agung Gde Oka<sup>2</sup>, Kadek Budi Santosa<sup>2</sup></span></p>
<ul style="list-style:none;"><li>
<p><span class="font5"><sup>1</sup> &nbsp;&nbsp;&nbsp;Resident of Surgery, Faculty of Medicine, Udayana University - Sanglah General Hospital, Bali.</span></p></li>
<li>
<p><span class="font5"><sup>2</sup> &nbsp;&nbsp;&nbsp;Division of Urology, Department of Surgery, Faculty of Medicine Udayana University - Sanglah General Hospital, Bali.</span></p></li></ul>
<p><span class="font5">*Corresponding author: </span><a href="mailto:khesavanyakrisna@gmail.com"><span class="font5">khesavanyakrisna@gmail.com</span></a><span class="font5">.</span></p>
<p><span class="font6" style="font-weight:bold;">ABSTRACT</span></p>
<p><span class="font6" style="font-weight:bold;">Objective: </span><span class="font6">To determine the predictive factors that influence the outcome of Double “J” (DJ) stent placement in stage IIIB cervical cancer patients with hydronephrosis complications. </span><span class="font6" style="font-weight:bold;">Methods: </span><span class="font6">An analytical observational study with a historical cohort was performed. Patients included in this study was patient with stage IIIB cervical cancer with hydronephrosis complication at Sanglah hospital. We analyzed the influence of time range since diagnosis until DJ stent placement, degree of hydronephrosis, and glomerular filtration rate on the outcomes of DJ stent placement namely: Lower urinary tract symptoms (LUTS), quality of life (QoL), and glomerular filtration rate changes (GFR). Data were tabulated and statistically analyzed using SPSS 25. </span><span class="font6" style="font-weight:bold;">Results: </span><span class="font6">Of the 44 samples, the mean age of the patients was 51,93 (±7.672) years. Late DJ stent placement increase the risk of severe LUTS (RR: 3.103; 95%CI: 1.319-7.301; p&lt;0.001) compared to patients with early DJ stent placement. We also found that a low glomerular filtration rate (bad renal function) is significantly associated with worse quality of life (RR: 1.917; 95%CI: 1.296-2.835; p&lt;0.001). </span><span class="font6" style="font-weight:bold;">Conclusion: </span><span class="font6">Delayed DJ stent placement is associated with severe LUTS symptoms, and poor renal function resulted in a poor quality of life.</span></p>
<p><span class="font6" style="font-weight:bold;">Keywords: </span><span class="font6">cervical cancer stage IIIB, hydronephrosis, DJ stent, glomerular filtration rate, lower urinary tract symptoms.</span></p>
<p><span class="font6" style="font-weight:bold;">DOI: </span><a href="https://doi.org/10.24843/JBN.2022.v06.i01.p01"><span class="font6" style="font-weight:bold;">https://doi.org/10.24843/JBN.2022.v06.i01.p01</span></a></p>
<h2><a name="bookmark2"></a><span class="font7" style="font-weight:bold;"><a name="bookmark3"></a>INTRODUCTION</span></h2>
<p><span class="font7">Annually, estimated around 15.000 new cases of cervical cancer in Indonesia. In Bali, cervical cancer is one of the most common cancer in women, especially at productive ages. Sanglah Central Hospital in Bali recorded 69 cases of cervical cancer treated from 2016 to 2017 with more than 90% of them being in the late stage.<sup>1</sup></span></p>
<p><span class="font7">One of the problems faced by late-stage cervical cancer patients is hydronephrosis complication. This complication resulted from direct invasion of the tumor, pressure from retroperitoneal metastatic mass, or lymph mass pressure toward the ureter.<sup>2</sup> Neglected hydronephrosis may cause irreversible obstructive nephropathy that will affect</span></p>
<p><span class="font7">patients' quality of life and might give rise to many other symptoms.<sup>2,3</sup> Double “J” stent placement is one of the options to manage this complication, and prevent obstructive uropathy in late-stage cervical cancer patients. The placement of the DJ stent hoped to manage the obstruction of the ureter, prevent the deterioration of renal function, improve quality of life, and prevent urinary tract symptoms in patients.<sup>3</sup> Study from Shehab, et al shows the improvement of glomerular filtration rates (GFR) that used as the parameter of renal function.<sup>4</sup> Some study by Al Marhoon, et al shows that 85.2% of patients with symptomatic hydronephrosis shows improvement of symptoms after DJ stent placement.<sup>5</sup> Yet on the other hand DJ stent</span></p>
<p><span class="font7">placements are known to cause some urinary complications such as hematuria, urinary tract infection, and pain. This complication is known to cause disturbance in patients’ quality of life (QoL).<sup>6</sup></span></p>
<p><span class="font7">This study aims to observe the factors that might influence the outcomes of the DJ stent placements in cervical cancer stage IIIB patients with hydronephrosis complications. The factors observed in this study include the time range from the diagnosis of cervical cancer to the time of DJ stent placements, the initial glomerular filtration rate, and the degree of hydronephrosis. The outcomes of DJ placements that we studied include the severity of lower urinary tract symptoms (LUTS), patient quality of life (QoL), and changes in glomerular filtration rates.</span></p>
<p><span class="font7" style="font-weight:bold;">METHODS</span></p>
<p><span class="font7" style="font-weight:bold;">Design, time, and place of the study</span></p>
<p><span class="font7">This study was an analytic observational study with a historical cohort design. The aim is to assess the association of predictive factors with the severity of LUTS, GFR changes, and quality of life in cervical cancer stage IIIB with hydronephrosis complication. Data regarding patients’ characteristics, staging, and time of DJ stent placement are obtained from patients’ medical records, then we follow patients' history and collected the follow-up data of the GFR after DJ stent placements, LUTS, and Quality of life scores. The study was conducted at Sanglah General Hospital, Bali, Indonesia from 1<sup>st</sup> January 2018 until 31<sup>st </sup>December 2019.</span></p>
<p><span class="font7" style="font-weight:bold;">Sample characteristics</span></p>
<p><span class="font7">We used total population sampling and obtained 44 samples. Patients included in this study are all cervical cancer patients stage IIIB with hydronephrosis complications that undergoing DJ stent placements in the Central Surgical Ward of Sanglah General Hospital during the period of the study. The diagnosis</span></p>
<p><span class="font7">of cervical cancer must be proven by pathological anatomy results, and hydronephrosis is diagnosed using ultrasound results. The exclusion criteria are incomplete medical record; patient with a history of chemo or radiotherapy; patient with severe comorbid outside of cervical cancer and hydronephrosis; history of urinary tract malignancy prior DJ stent placements, history of hemodialysis, and patient with a history of using medication that could alter renal function examination (e.g., long term analgetic).</span></p>
<p><span class="font7" style="font-weight:bold;">Data analysis</span></p>
<p><span class="font7">Data obtained from the medical records are tabulated using SPSS version 25. Sample characteristics are presented as continuous and categorical data. Continuous data are presented as mean and standard deviation (SD), and categorical data are presented in frequency and percentages. For analytical data, we categorized data into two groups. For Independent variables, the time range variables are grouped into Late DJ stent placements (≥2 months), and early DJ stent placement (&lt;2 months). Degree of hydronephrosis are grouped into severe and mild-to-moderate, Glomerular filtration rate calculated by estimated glomerular filtration rate using Cockroft-Gault formula, and grouped into good GFR (≥60 mL/minutes/1.73 m<sup>2</sup>) and bad GFR (&lt;60 mL/minutes/1.73 m<sup>2</sup>). Dependent variables consist of LUTS, GFR changes, and QoL. LUTS was measured by International Prostate Symptom Score (IPSS) and grouped into mild-to-moderate symptoms (IPSS ≤ 19) and severe symptoms (IPSS &gt;&nbsp;19). QoL is measured by The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C-30) that has already been translated and validated in Bahasa Indonesia. Grouped into good QoL (Total score &gt;&nbsp;500), and bad QoL (total score</span></p>
<p><span class="font7">≤ 500). GFR changes are the difference of GFR before DJ stent placement and 2 months after DJ stent placements. It is grouped into increased GFR and decreased GFR.</span></p>
<p><span class="font7">We then conduct bivariate analysis using crosstabs between each independent variable as a predictive factor, and each dependent variable as an outcome. The statistical tests are conducted using the Chi-Square test. We also calculated the relative risk (RR) and 95% confidence interval (95%CI) for each crosstab.</span></p>
<h2><a name="bookmark4"></a><span class="font7" style="font-weight:bold;"><a name="bookmark5"></a>RESULTS</span></h2>
<h2><a name="bookmark6"></a><span class="font7" style="font-weight:bold;"><a name="bookmark7"></a>Characteristics of the study</span></h2>
<p><span class="font7">As many as105 patients registered to undergo DJ stent placements during the study period. 80 of those patients are patients with cervical cancer stage IIIB, with 60 patients</span></p>
<p><span class="font7">conducting DJ stent placement on one side of the ureter. Of 60 patients that satisfy inclusion criteria, 16 of them were excluded from the study due to incomplete medical records. 44 patients are included and analyzed in this study without any loss to follow-up.</span></p>
<p><span class="font7">The mean ages of the patients are 51.93 (SD: 7.672) years old. From the independent variables, patients divided into severe (n:11) and mild to moderate (n:33) hydronephrosis; Late (n:29) and early (n:15) time span; and also good renal function (n:23), and bad renal function (n:21). We found that 28 patients (63.3%) developed severe LUTS, 34 (77.3%) patients have decreased GFR, and 33 patients (75%) have bad QoL. The full characteristics of the samples can be seen in </span><span class="font7" style="font-weight:bold;">Table 1</span><span class="font7">.</span></p>
<p><span class="font6" style="font-weight:bold;">Table 1. </span><span class="font6">Sample Characteristics</span></p>
<table border="1">
<tr><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">Variables</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">N: 44</span></p></td></tr>
<tr><td style="vertical-align:top;"></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">(Mean </span><span class="font1" style="font-weight:bold;">± </span><span class="font6" style="font-weight:bold;">SD)</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Age (years)</span></p></td><td style="vertical-align:top;">
<p><span class="font6">51.93 ± 7.672</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Parity (n)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">2.02 ± .549</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Haemoglobin levels (mg/dL)</span></p></td><td style="vertical-align:top;">
<p><span class="font6">10.1239 ± 2.05875</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Time span (months)</span></p></td><td style="vertical-align:top;">
<p><span class="font6">1.95 ± .914</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">GFR before DJ stent (mL/minutes/1.73 m<sup>2)</sup></span></p></td><td style="vertical-align:top;">
<p><span class="font6">64.2500 ± 26.66687</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">GFR after DJ stent (mL/minutes/1.73 m<sup>2)</sup></span></p></td><td style="vertical-align:top;">
<p><span class="font6">43.3182 ± 30.83020</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">GFR Difference after DJ stent (mL/minutes/1.73 m<sup>2</sup>)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">-20.9318 ± 26.54123</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Hydronephrosis degree</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6" style="font-weight:bold;">n(%)</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Severe</span></p></td><td style="vertical-align:top;">
<p><span class="font6">11 (25.0)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Mild-to-moderate</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">33 (75.0)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Quality of Life (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Bad</span></p></td><td style="vertical-align:top;">
<p><span class="font6">33 (75.0)</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Good</span></p></td><td style="vertical-align:top;">
<p><span class="font6">11 (25.0)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">LUTS (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Severe</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">28 (63.6)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Mild-to-moderate</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">16 (36.4)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Time range (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font6">Late</span></p></td><td style="vertical-align:top;">
<p><span class="font6">29 (65.9)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Early</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">15 (34.1)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">GFR Difference (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Decreased</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">34 (77.3)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Increased</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">10 (22.7)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Initial GFR (%)</span></p></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Bad renal function</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">21 (47.7)</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font6">Good renal function</span></p></td><td style="vertical-align:bottom;">
<p><span class="font6">23 (52.3)</span></p></td></tr>
</table>
<h2><a name="bookmark8"></a><span class="font7" style="font-weight:bold;"><a name="bookmark9"></a>The association of the predictive factors with the severity of LUTS</span></h2>
<p><span class="font7">We conducted the bivariate analysis using crosstabs and Chi-Square statistical analysis to assess the association of several predictive factors to the risk of developing severe LUTS. We found that late DJ stent placements (DJ</span></p>
<p><span class="font7">stent placed after more than 2 months) are associated with an increased risk of Severe LUTS (RR: 3.103; 95%CI: 1.319-7.301; p&lt;0.001). However the degree of hydronephrosis and initial GFR did not have a significant association with the severity of LUTS (</span><span class="font7" style="font-weight:bold;">Table 2</span><span class="font7">).</span></p>
<p><span class="font6" style="font-weight:bold;">Table 2. </span><span class="font6">The distribution and association of various predictive factors to the severity of LUTS after</span></p>
<p><span class="font6">DJ stent placements</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Variables</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Severe LUTS</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Mild-to-moderate LUTS</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">RR</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">95% CI</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">p</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Time range</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Late DJ stent</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">24 (82.8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">5 (17.2%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">3.103</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">1.319-7.301</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">&lt; 0.001*</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Early DJ stent</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">4 (26.7%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">11 (73.3%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Hydronephrosis degree</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Severe</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">7 (63.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">4 (36.4%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">1.235</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.708-2.154</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.484</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Mild-to-moderate</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">17 (51.5%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">16 (48.5%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">GFR</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Bad renal function</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">10 (47.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">11 (52.4)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.782</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.449-1.363</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.378</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Good renal function</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">14 (60.9%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">9 (39.1%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
</table>
<p><span class="font5" style="font-weight:bold;">*</span><span class="font5">Statistically significant (Chi-square test)</span></p>
<h2><a name="bookmark10"></a><span class="font7" style="font-weight:bold;"><a name="bookmark11"></a>The association of the predictive factors with the GFR changes</span></h2>
<p><span class="font7">We found that none of the predictive factors have a significant association with DJ stent placements outcomes (</span><span class="font7" style="font-weight:bold;">Table 3</span><span class="font7">). Late DJ stents have a higher frequency of having decreased GFR (79.3%) compared with early</span></p>
<p><span class="font7">DJ stent placements (73.3%), however, the difference is not statistically significant. The same result was also found for hydronephrosis degree and initial GFR that indicate the difference is small and not significant that it can be attributed to chance only (null hypothesis).</span></p>
<p><span class="font6" style="font-weight:bold;">Table 3. </span><span class="font6">The distribution and association of various predictive factors to the GFR changes after DJ</span></p>
<p><span class="font6">stent placements</span></p>
<table border="1">
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Variables</span></p></td><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Decreased GFR</span></p></td><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Increased GFR</span></p></td><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">RR</span></p></td><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">95% CI</span></p></td><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">p</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Time range</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Late DJ stent</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">23 (79.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">6 (20.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">1.082</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.757-1.546</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.714</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5">Early DJ stent</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">11 (73.3%)</span></p></td><td style="vertical-align:bottom;">
<p><span class="font5">4 (26.7%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Hydronephrosis degree</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Severe</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">8 (72.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">3 (27.3%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.923</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.617-1.381</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.692</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Mild-to-moderate</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">26 (78.8%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">7 (21.2%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">GFR</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Bad renal function</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">15 (71.4%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">6 (28.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.865</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.622-1.202</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.481</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Good renal function</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">19 (82.6%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">4 (17.4%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
</table>
<p><span class="font5" style="font-weight:bold;">*</span><span class="font5">Statistically significant (Chi-square test)</span></p>
<h2><a name="bookmark12"></a><span class="font7" style="font-weight:bold;"><a name="bookmark13"></a>The association of the predictive factors with the quality of life</span></h2>
<p><span class="font7">For the quality of life outcomes, we found that all patients with bad renal function (GFR</span><span class="font2">≤</span><span class="font7">60) have bad quality of life (EORTC QLQ C-30</span></p>
<p><span class="font7">score </span><span class="font2">≤ </span><span class="font7">500), with bad initial GFR, is associated with increased risk of having a bad quality of life (RR: 1.917; 95%CI: 1.2962.835; p&lt;0.001) (</span><span class="font7" style="font-weight:bold;">Table 4</span><span class="font7">).</span></p>
<p><span class="font6" style="font-weight:bold;">Table 4. </span><span class="font6">The distribution and association of various predictive factors to the patient’s quality of life after DJ stent placements</span></p>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Variables</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Bad QoL</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">Good QoL</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">RR</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">95% CI</span></p></td><td style="vertical-align:top;">
<p><span class="font5" style="font-weight:bold;">p</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">Time range</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Late DJ stent</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">20 (69.0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">9 (31.0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.796</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.581-1.090</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0.282</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Early DJ stent</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">13 (86.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">2 (13.3%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">Hydronephrosis</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font5" style="font-weight:bold;">degree</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font5">Severe</span></p></td><td style="vertical-align:top;">
<p><span class="font5">9 (81.8%)</span></p></td><td style="vertical-align:top;">
<p><span class="font5">2 (18.2%)</span></p></td><td style="vertical-align:top;">
<p><span class="font5">1.125</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.794-1.594</span></p></td><td style="vertical-align:top;">
<p><span class="font5">0.701</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Mild-to-moderate</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">24 (72.7%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">9 (27.3%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5" style="font-weight:bold;">GFR</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Bad renal function</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">21 (100.0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">0 (0.0%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">1.917</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">1.296-2.835</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">&lt;0.001*</span></p></td></tr>
<tr><td style="vertical-align:middle;">
<p><span class="font5">Good renal function</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">12 (52.2%)</span></p></td><td style="vertical-align:middle;">
<p><span class="font5">11 (47.8%)</span></p></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td><td style="vertical-align:top;"></td></tr>
</table>
<p><span class="font5" style="font-weight:bold;">*</span><span class="font5">Statistically significant (Chi-square test)</span></p>
<h2><a name="bookmark14"></a><span class="font7" style="font-weight:bold;"><a name="bookmark15"></a>DISCUSSION</span></h2>
<p><span class="font7">Ureteral obstruction caused by the advancement of cervical cancer might cause further complications if it happened over a long time. Obstructive uropathy might cause abnormality of renal tissue structure and function. Most of the abnormalities are asymptomatic until they reach severe destruction of renal tissues that leads to deterioration of renal function. This can give rise to various symptoms such as uremia, disturbance of fluid and electrolytes balances, urinary tract infections, anemia, and renal failure that leads to morbidity and mortality.<sup>6 </sup>This shows the importance of ureter deobstruction to prevent irreversible loss of renal function.</span></p>
<p><span class="font7">DJ stent placement is one of the methods to deobstruct the ureter in patients with cervical cancer stage IIIB. This study aimed to observe the factors associated with the improvements of outcomes for the patients who underwent DJ stent placements. We observe three factors in this study which are the time range from the diagnosis of cervical cancer to the DJ stent</span></p>
<p><span class="font7">placements; initial GFR, and degree of hydronephrosis. Of the 44 samples that we obtained, we found that late DJ stent placement (DJ stent placements conducted in more than 2 months after cervical cancer diagnosis) increased the risk of severe LUTS after DJ stent placements by 3.103 times compared to a patient with early DJ stent placement (RR: 3.103; 95%CI: 1.319-7.301; p&lt;0.001). We also found that a low glomerular filtration rate (GFR &lt;60) is significantly associated with worse quality of life compared to good initial GFR (≥60) (RR: 1.917; 95%CI: 1.296-2.835; p&lt;0.001). We found no statistically significant association for other variables that we assess.</span></p>
<p><span class="font7">Irreversible deterioration of renal function in pigs happened after 6 weeks of obstruction. Microscopic findings that may cause the decrease of renal function are the collapse of the glomerulus, atrophy of renal tubules, and interstitial fibrosis.7 Our study did not find a significant association between the time range to DJ stent placement and the GFR improvements, However, our study does show</span></p>
<p><span class="font7">that late DJ stent placements indicating prolonged renal obstruction do increase the risk of severe LUTS after DJ stent placements.</span></p>
<p><span class="font7">The also observes the association of hydronephrosis severity with the outcomes of DJ stent placements. We found there is no significant association between the degrees of hydronephrosis all of the DJ stent outcomes observed in the study. This finding is in line with the study by Gumilar, et al that also did not find any association of hydronephrosis degree with the succession of DJ stent placements in cervical cancer patients.<sup>8</sup></span></p>
<p><span class="font7">Quality of life is also one of the important outcomes that shows the actual improvements that can be felt by the patients after DJ stents placements. Our study found that although late DJ stent placements increase the risk of severe LUTS, It is not significantly associated with worse quality of life compared to early DJ stent placements. This may happen because the patients with cervical cancer already have other symptoms that reduced their quality of life and such as cancer pain, disturbance of daily activity, etc, even without LUTS. This might result in similar QoL in patients with severe LUTS and mild-to-moderate LUTS. Our study however found that initial renal function is associated with worse quality of life. None of the patients with bad GFR have a good QoL. Bad GFR is associated with an increased risk of bad QoL compared to patients with good GFR (RR: 1.917, 95% CI 1.296-2.835, P&lt;0.001).</span></p>
<p><span class="font7">Our study has several limitations. A small sample size might reduce the power of our study to detect the difference in the result statistically. Our historical cohort design also might cause biased data caused by excluding patients with incomplete medical history. Uncontrolled confounding variables also might bias our results, since lack of methods to control the confounding variables.</span></p>
<h2><a name="bookmark16"></a><span class="font7" style="font-weight:bold;"><a name="bookmark17"></a>CONCLUSION</span></h2>
<p><span class="font7">Delayed DJ stent placement is associated with severe LUTS symptoms, and poor renal function glomerular filtration rate resulting in a poor quality of life. This study can be used as a preliminary study to further study and improve patients with cervical cancer treatments to improve patients’ quality of life and prevent complications.</span></p>
<h2><a name="bookmark18"></a><span class="font7" style="font-weight:bold;"><a name="bookmark19"></a>ACKNOWLEDGEMENTS</span></h2>
<p><span class="font7">The author would like to thank all research participants and everyone supporting the study.</span></p>
<h2><a name="bookmark20"></a><span class="font7" style="font-weight:bold;"><a name="bookmark21"></a>DISCLOSURE</span></h2>
<p><span class="font7">The authors declared no conflict of interest exists regarding this research.</span></p>
<h2><a name="bookmark22"></a><span class="font7" style="font-weight:bold;"><a name="bookmark23"></a>REFERENCES</span></h2>
<ul style="list-style:none;"><li>
<p><span class="font7">1. &nbsp;&nbsp;&nbsp;Darmayasa IM, Aryana MBD, Surya HW.</span></p></li></ul>
<p><span class="font7" style="font-style:italic;">Kualitas hidup pasien kanker serviks yang dirawat di ruang cempaka ginekologi RSUP Sanglah Denpasar</span><span class="font7">. Presented at PIT HOGSI X; 2017 April 11; Jakarta; 2017.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font7">2. &nbsp;&nbsp;&nbsp;Goldfarb DA, Poggio ED. Etiology, Pathogenesis, and Management of Renal Failure. In: McDougal WS, Wein AJ, Kavoussi LR, et al, editors. </span><span class="font7" style="font-style:italic;">Campbell-Walsh Wein Handbook of Urology, 10<sup>th</sup> ed</span><span class="font7">. Philadelphia: Elsevier Saunders; 2012. p.1193-225.</span></p></li>
<li>
<p><span class="font7">3. &nbsp;&nbsp;&nbsp;Hodson CJ. Post-obstructive renal atrophy (nephropathy). </span><span class="font7" style="font-style:italic;">Br Med Bull</span><span class="font7">. 1972;28:237-40.</span></p></li>
<li>
<p><span class="font7">4. &nbsp;&nbsp;&nbsp;Shehab M, El Helali A, Abdelkhalek M, et. al. Role of ureteric stents in relieving obstruction in patients with obstructive uropathy. </span><span class="font7" style="font-style:italic;">Urol Ann</span><span class="font7">. 2013;5:148-51.</span></p></li>
<li>
<p><span class="font7">5. &nbsp;&nbsp;&nbsp;Al-Marhoon MS, &nbsp;&nbsp;&nbsp;Shareef O,</span></p></li></ul>
<p><span class="font7">Venkiteswaran KP. Complications and outcomes of JJ stenting of the ureter in</span></p>
<p><span class="font7">urological practice: &nbsp;&nbsp;A single-center</span></p>
<p><span class="font7">experience. </span><span class="font7" style="font-style:italic;">Arab J Urol</span><span class="font7">. 2012;10:372-7.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font7">6. &nbsp;&nbsp;&nbsp;Miyaoka R, Monga M. Ureteral stent discomfort: Etiology and management. </span><span class="font7" style="font-style:italic;">Indian J Urol</span><span class="font7">. 2009;25:455-60.</span></p></li>
<li>
<p><span class="font7">7. &nbsp;&nbsp;&nbsp;Singh I, Strandhoy JW, Assimos DG. Pathophysiology of urinary tract obstruction. In: McDougal WS, Wein AJ, Kavoussi LR, et al, editors. </span><span class="font7" style="font-style:italic;">Campbell-</span></p></li></ul>
<p><span class="font7" style="font-style:italic;">Walsh Wein Handbook of Urology, 10<sup>th</sup> ed</span><span class="font7">. Philadelphia: Elsevier Saunders; 2012. p.1087-121.</span></p>
<ul style="list-style:none;"><li>
<p><span class="font7">8. &nbsp;&nbsp;&nbsp;Gumilar OB, Soebadi DM, Djojodimedjo T, et al. Oral phenazopyridine HCl for ureter orifice identification and retrograde stenting. </span><span class="font7" style="font-style:italic;">Indonesian J Urol</span><span class="font7">. 2015;22:21-7.</span></p></li></ul>
<p><span class="font6">7</span></p>